Custom Health Achieves 70% Increase in Quarterly Revenue in Q2-2026 and Advances Medication Management Platform with Evergreen Pharmacy and Spencer Health Solutions Acquisitions
For the three months ended June 30, 2026, Custom Health achieved quarterly revenue of US$7.4 million, an increase of 70% from Q2-2025. The results reflect the acquisition of InnovativeRx during the period. The equity pickup for IRX accounts for an acquisition date of June 5, 2026. Proforma Revenue for the combined entity for the 3 months ended June 30, 2026 is US$14.3 million(1). Subsequent to quarter-end, Custom Health entered into a binding letter
Technology, Pharmaceuticals, Health
2026-08-17 6:07 PM EDT | Custom Health Holdings Inc.
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnology, Pharmaceuticals, Health
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psy
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-08-14 8:14 AM EDT | Rhelion Life Sciences Corp.
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026. The new ticker symbol,
Healthcare and Hospitals, Health
2026-08-14 1:22 AM EDT | Cosmo Pharmaceuticals N.V.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the pri
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-13 4:11 PM EDT | Elite Pharmaceuticals, Inc.
Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, today announced an update on recent operational milestones and expansion progress, underscoring its continued growth in telecommunications infrastructure. Core Business and Tower Operations FTF maintains a portfolio of 28 cellular
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-08-13 4:05 PM EDT | Akanda Corp
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
Healthcare and Hospitals, Health
2026-08-13 12:07 PM EDT | Adia Med Inc.
Charlotte's Web Reports Second Quarter 2026 Financial Results
Louisville, Colorado--(Newsfile Corp. - August 13, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended June 30, 2026. All amounts are expressed in U.S. dollars unless otherwise indicated. "The second quarter fundamentally changed Charlotte's Web's financial position.
2026-08-13 7:07 AM EDT | Charlotte's Web Holdings, Inc.
LIS Technologies Announces $6.2M Acquisition of the 37,800sq-ft K-1580 Facility at the Historic Heritage Center in Oak Ridge, Tennessee to Expand its Medical and Stable Isotope and Nuclear Fuel Cycle Initiatives
Oak Ridge, Tennessee--(Newsfile Corp. - August 12, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a developer of proprietary advanced laser technology and the only USA-origin and patented laser uranium enrichment company, is pleased to announce that it has expanded its presence in Oak Ridge, Tennessee's historic Heritage Center and K-25 Enrichment Site with the acquisition of the K-1580 Building, a prominent, newly-renovated, three-level, 37,803 square-foot facility, for a to
Technology, Mining and Metals, Energy, Health
2026-08-12 8:59 AM EDT | LIS Technologies Inc.
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnology, Pharmaceuticals, Health
2026-08-12 8:23 AM EDT | Hemostemix Inc.
Experience Onward Acquires 36 Acre Colorado Property to Launch Onward Ranch, a Legal Psilocybin and Wellness Retreat Destination
Denver, Colorado--(Newsfile Corp. - August 11, 2026) - Experience Onward, founded by former NHL player and two time Stanley Cup champion Daniel Carcillo, today announced the acquisition of a private, 36 acre mountain property in Colorado that is now progressing through the state licensing process to become a legal psilocybin retreat destination. Named Onward Ranch, the property is being developed as a first of its kind residential retreat environment designed to bring legal, regu
2026-08-11 9:00 AM EDT | Experience Onward
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m. to both in-person students and those joining live online.
Healthcare and Hospitals, Health
2026-08-11 8:00 AM EDT | Adia Med Inc.
ONE HEMP Welcomes Senate Continuing Resolution Passage, Calls for Clear Distinctions in Hemp Policy
Washington, D.C.--(Newsfile Corp. - August 11, 2026) - ONE HEMP welcomed the Senate's passage of a continuing resolution extending naturally-occurring hemp product ban until December 11, preventing a broad restriction on full-spectrum hemp products from taking effect on November 12 and providing Congress additional time to advance sound, science-based legislation. The extension creates an opportunity for lawmakers to develop a regulatory framework that protects consumers while pr
2026-08-11 7:23 AM EDT | OneHemp
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue gener
Technology, Biotechnology, Health
2026-08-11 6:00 AM EDT | Restart Life Sciences Corp.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company's financial and o
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 4:54 PM EDT | Elite Pharmaceuticals, Inc.